Get the Stockscreener App
4.37
4.38%
-0.20
Pluri Inc stock is traded at $4.37, with a volume of 4,543.
It is down -4.38% in the last 24 hours and down -9.34% over the past month.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
See More
Previous Close:
$4.57
Open:
$4.6154
24h Volume:
4,543
Relative Volume:
0.25
Market Cap:
$34.92M
Revenue:
$598.00K
Net Income/Loss:
$-21.81M
P/E Ratio:
-1.0607
EPS:
-4.12
Net Cash Flow:
$-16.66M
1W Performance:
-2.91%
1M Performance:
-9.34%
6M Performance:
-21.94%
1Y Performance:
-24.53%
1-Day Range:
$4.4485
$4.6154
1-Week Range:
$4.30
$4.6154
52-Week Range:
$3.33
$7.13
Pluri Inc Stock (PLUR) Company Profile
Name
Pluri Inc
Sector
Industry
Phone
972-74-710-7171
Address
MATAM ADVANCED TECHNOLOGY PARK, HAIFA
Compare PLUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLUR
Pluri Inc
|
4.46 | 35.25M | 598.00K | -21.81M | -16.66M | -4.12 |
|
ONC
Beone Medicines Ltd Adr
|
245.78 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.49 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.09 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.83 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Pluri Inc Stock (PLUR) Latest News
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials - The Malaysian Reserve
Pluri Inc. reschedules 2025 annual meeting By Investing.com - Investing.com Nigeria
Pluri Inc. reschedules 2025 annual meeting - Investing.com
Pluri (NASDAQ:PLUR) vs. CARGO Therapeutics (NASDAQ:CRGX) Head-To-Head Review - Defense World
Cellular Therapeutics Market Poised for Explosive Growth, Driven by Innovative Companies - citybuzz -
4 Stocks To Watch In The $47 Billion Cellular Therapeutics Market - FinancialContent
Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion - TradingView
Pluri Achieves 400% Revenue Surge as Biotech Pioneer Enters $130B Cacao and Coffee Markets - Stock Titan
Pluri (NASDAQ:PLUR) & Qiagen (NYSE:QGEN) Head to Head Contrast - Defense World
Pluri: Fiscal Q3 Earnings Snapshot - New Haven Register
Pluri Regains Nasdaq Compliance Before Deadline - TipRanks
Renaissance Technologies LLC Boosts Stock Position in Pluri Inc. (NASDAQ:PLUR) - Defense World
Q&A with Alejandro Weinstein, Pluri Board of Directors - citybiz
Pluri Inc. sets date for 2025 shareholder meeting By Investing.com - Investing.com Canada
Pluri Inc. sets date for 2025 shareholder meeting - Investing.com
Pluri acquires 71% stake in Kokomodo - Food Business News
Pluri Inc. acquires majority stake in Kokomodo Ltd. By Investing.com - Investing.com Canada
Pluri Acquires 71% Of Kokomodo To Advance Climate-Resilient Cultivated Cacao Production - Nasdaq
Pluri Inc. acquires majority stake in Kokomodo Ltd. - Investing.com
$13.5B Cacao Market Disruption: Pluri Acquires Cellular Agriculture Pioneer Kokomodo for Climate-Resilient Future - Stock Titan
Pluri Inc. enters agreement, issues pre-funded warrants - Investing.com Australia
Pluri Inc. enters agreement, issues pre-funded warrants By Investing.com - Investing.com Canada
Pluristem stock soars to 52-week high, hits $6.63 By Investing.com - Investing.com South Africa
Pluristem stock soars to 52-week high, hits $6.63 - Investing.com Australia
DarioHealth Announces CFO Transition - The Malaysian Reserve
DarioHealth Announces CFO Transition - Benzinga
DarioHealth Taps Israeli CFO Excellence Award Winner to Lead Next Growth Phase - Stock Titan
Pluri Inc. subsidiary loses $4.2 million NIAID contract By Investing.com - Investing.com Canada
Pluri Inc. subsidiary loses $4.2 million NIAID contract - Investing.com Australia
Pluri IncPluri Biotech Receives Termination Notice From Niaid Of ContractSEC Filing - marketscreener.com
Analyzing X4 Pharmaceuticals (NASDAQ:XFOR) & Pluri (NASDAQ:PLUR) - Defense World
Pluri Inc. (NASDAQ:PLUR) Short Interest Update - Defense World
Pluri’s immune cell expansion technologies gain patents - Yahoo Finance
Pluri Announces Expansion of Intellectual Property Portfolio wit - GuruFocus
Pluri secures patents for cancer cell therapy expansion tech By Investing.com - Investing.com South Africa
Pluri Inc. Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel - MarketScreener
Pluri secures patents for cancer cell therapy expansion tech - Investing.com India
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel - TradingView
Pluri CEO Yaky Yanay on pioneering cell-tech solutions for global needs - Proactive financial news
Pluri Inc Stock (PLUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):